Hybrid-drug design targeting Pseudomonas aeruginosa DHPS and DHFR

Frontiers in Bioscience - Elite

Volumn 5 E, Issue 3, 2013, Pages 864-882

  Jayaraman, Premkumar ^a   Sakharkar, Kishore R ^b   Daniel, Lim Chu Sing ^a   Siddiqi, Mohammad Imran ^c   Dhillon, Sarinder Kaur ^d   Sakharkar, Meena K ^e  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b OmicsVista   (Singapore)

^c CENTRAL DRUG RESEARCH INSTITUTE   (India)

^d UNIVERSITY OF MALAYA   (Malaysia)

^e UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Dihydrofolate reductase; Dihydropteroate synthase; Drug resistance; Dual action compounds; Hybrid drug design; Multi target inhibitors; Phytochemicals

Indexed keywords

4 HYDROXYBENZOIC ACID; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; EPIGALLOCATECHIN GALLATE; EUDESMIC ACID; GALLIC ACID; METHOTREXATE; MYRICETIN; PLANT MEDICINAL PRODUCT; PROTOCATECHUIC ACID; QUERCETIN; SULFADIAZINE; SULFAMETHOXAZOLE; SYRINGIC ACID; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANILLIC ACID;

ARTICLE; BINDING AFFINITY; BINDING SITE; CHEMICAL STRUCTURE; COMPUTER MODEL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG STABILITY; DRUG TARGETING; ENZYME INHIBITION; HYBRIDIZATION; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; MUTAGENIC ACTIVITY; NONHUMAN; PHYSICAL CHEMISTRY; PSEUDOMONAS AERUGINOSA; QUANTUM CHEMISTRY; REPRODUCTIVE TOXICITY;

PSEUDOMONAS AERUGINOSA;

EID: 84884342953     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. E. B. M. Breidenstein, C. de la Fuente-Núñez and R. E. W. Hancock: Pseudomonas aeruginosa: All roads lead to resistance. Trends in Microbiology, 19(8), 419-426 (2011)
2. P. A. Lambert: Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. Journal of the Royal Society of Medicine, Supplement, 95(41), 22-26 (2002)
3. H. W. Boucher, G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg and J. Bartlett: Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases, 48(1), 1-12 (2009)
4. doi:10.1086/595011 4. M. G. Page and J. Heim: Prospects for the next anti-Pseudomonas drug. Current Opinion in Pharmacology, 9(5), 558-565 (2009)
5. H. Brötz-Oesterhelt and N. A. Brunner: How many modes of action should an antibiotic have? Current Opinion in Pharmacology, 8(5), 564-573 (2008)
6. A. L. Hopkins: Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682-690 (2008)
7. V. Pokrovskaya and T. Baasov: Dual-acting hybrid antibiotics: A promising strategy to combat bacterial resistance. Expert Opinion on Drug Discovery, 5(9), 883-902 (2010)
8. R. Morphy and Z. Rankovic: Designing multiple ligands-Medicinal chemistry strategies and challenges. Current Pharmaceutical Design, 15(6), 587-600 (2009)
9. R. Morphy and Z. Rankovic: Fragments, network biology and designing multiple ligands. Drug Discovery Today, 12(3-4), 156-160 (2007)
10. E. Chamot, E. B. El Amari, P. Rohner and C. Van Delden: Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrobial Agents and Chemotherapy, 47(9), 2756-2764 (2003)
11. M. Bassetti, E. Righi and C. Viscoli: Pseudomonas aeruginosa serious infections: Mono or combination antimicrobial therapy? Current Medicinal Chemistry, 15(5), 517-522 (2008)
12. S. J. Johnson, E. J. Ernst and K. G. Moores: Is double coverage of gram-negative organisms necessary? American Journal of Health-System Pharmacy, 68(2), 119-124 (2011)
13. K. A. Traugott, K. Echevarria, P. Maxwell, K. Green and J. S. Lewis Ii: Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy, 31(6), 598-608 (2011)
14. H. Labischinski, J. Cherian, C. Calanasan and R. S. Boyce: Hybrid Antimicrobial Compounds and Their Use. In, (2010)
15. V. Pokrovskaya, V. Belakhov, M. Hainrichson, S. Yaron and T. Baasov: Design, synthesis, and evaluation of novel fluoroquinolone-Aminoglycoside hybrid antibiotics. Journal of Medicinal Chemistry, 52(8), 2243-2254 (2009)
16. S. Bera, G. G. Zhanel and F. Schweizer: Evaluation of amphiphilic aminoglycoside-peptide triazole conjugates as antibacterial agents. Bioorganic and Medicinal Chemistry Letters, 20(10), 3031-3035 (2010)
17. G. R. Zimmermann, J. Lehár and C. T. Keith: Multitarget therapeutics: when the whole is greater than the sum of the parts. Drug Discovery Today, 12(1-2), 34-42 (2007)
18. S. Hawser, S. Lociuro and K. Islam: Dihydrofolate reductase inhibitors as antibacterial agents. Biochemical Pharmacology, 71(7), 941-948 (2006)
19. P. Huovinen: Resistance to trimethoprimsulfamethoxazole. Clinical Infectious Diseases, 32(11), 1608-1614 (2001)
20. T. Köhler, M. Kok, M. Michea-Hamzehpour, P. Plesiat, N. Gotoh, T. Nishino, L. K. Curty and J. C. Pechere: Multidrug efflux in intrinsic resistance to trimethoprim and sulfamethoxazole in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 40(10), 2288-2290 (1996)
21. S. P. James, I. Jamie, S. S. Ian, M.: Folate Biosynthesis-Reappraisal of Old and Novel Targets in the Search for New Antimicrobials. The Open Enzyme Inhibition Journal, 1, 12-33 (2008)
22. K. E. Hevener, M. K. Yun, J. Qi, I. D. Kerr, K. Babaoglu, J. G. Hurdle, K. Balakrishna, S. W. White and R. E. Lee: Structural studies of pterin-based inhibitors of dihydropteroate synthase. Journal of Medicinal Chemistry, 53(1), 166-177 (2010)
23. B. C. Bennett, H. Xu, R. F. Simmerman, R. E. Lee and C. G. Dealwis: Crystal structure of the anthrax drug target, Bacillus anthracis dihydrofolate reductase. Journal of Medicinal Chemistry, 50(18), 4374-4381 (2007)
24. M. D. Navarro-Martínez, E. Navarro-Perán, J. Cabezas-Herrera, J. Ruiz-Gómez, F. García-Cánovas and J. N. Rodríguez-López: Antifolate activity of epigallocatechin gallate against Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy, 49(7), 2914-2920 (2005)
25. P. Jayaraman, K. R. Sakharkar, L. C. Sing, V. T. K. Chow and M. K. Sakharkar: Insights into antifolate activity of phytochemicals against Pseudomonas aeruginosa. Journal of Drug Targeting, 19(3), 179-188 (2011)
26. P. Jayaraman, M. K. Sakharkar, C. S. Lim, T. H. Tang and K. R. Sakharkar: Activity and interactions of antibiotic and phytochemical combinations against pseudomonas aeruginosa in vitro. International Journal of Biological Sciences, 6(6), 556-568 (2010)
27. M. K. Sakharkar, P. Jayaraman, W. M. Soe, V. T. K. Chow, L. C. Sing and K. R. Sakharkar: In vitro combinations of antibiotics and phytochemicals against Pseudomonas aeruginosa. Journal of Microbiology, Immunology and Infection, 42(5), 364-370 (2009)
28. S. Gibbons, E. Moser and G. W. Kaatz: Catechin gallates inhibit multidrug resistance (MDR) in Staphylococcus aureus. Planta Medica, 70(12), 1240-1242 (2004)
29. S. Hemaiswarya, A. K. Kruthiventi and M. Doble: Synergism between natural products and antibiotics against infectious diseases. Phytomedicine, 15(8), 639-652 (2008)
30. J. M. Rollinger: Accessing target information by virtual parallel screening-The impact on natural product research. Phytochemistry Letters, 2(2), 53-58 (2009)
31. M. Saleem, M. Nazir, M. S. Ali, H. Hussain, Y. S. Lee, N. Riaz and A. Jabbar: Antimicrobial natural products: An update on future antibiotic drug candidates. Natural Product Reports, 27(2), 238-254 (2010)
32. F. E. Koehn and G. T. Carter: The evolving role of natural products in drug discovery. Nature Reviews Drug Discovery, 4(3), 206-220 (2005)
33. D. J. Newman and G. M. Cragg: Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010. Journal of Natural Products (2012)
34. A. Ganesan: The impact of natural products upon modern drug discovery. Current Opinion in Chemical Biology, 12(3), 306-317 (2008)
35. T. P. T. Cushnie and A. J. Lamb: Antimicrobial activity of flavonoids. International Journal of Antimicrobial Agents, 26(5), 343-356 (2005)
36. X. H. Ma, Z. Shi, C. Tan, Y. Jiang, M. L. Go, B. C. Low and Y. Z. Chen: In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening. Pharm Res, 27(5), 739-49 (2010) doi:10.1007/s11095-010-0065-2
37. P. Agarwal and D. B. Searls: Literature mining in support of drug discovery. Briefings in Bioinformatics, 9(6), 479-492 (2008)
38. R. Guha, M. T. Howard, G. R. Hutchison, P. Murray-Rust, H. Rzepa, C. Steinbeck, J. Wegner and E. L. Willighagen: The Blue ObeliskInteroperability in Chemical Informatics. Journal of Chemical Information and Modeling, 46(3), 991-998 (2006). doi:10.1021/ci050400b
39. I. Wavefunction: SPARTAN. In, 18401 Von Karman Avenue, Suite 370 Irvine, CA 92612 USA (2010)
40. W. Koch and M. C. Holthausen. A Chemist's Guide to Density Functional Theory (2000)
41. Y. H. Zhao, M. H. Abraham, J. Le, A. Hersey, C. N. Luscombe, G. Beck, B. Sherborne and I. Cooper: Rate-limited steps of human oral absorption and QSAR studies. Pharmaceutical Research, 19(10), 1446-1457 (2002)
42. K. Arnold, L. Bordoli, J. Kopp and T. Schwede: The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling. Bioinformatics, 22(2), 195-201 (2006)
43. A. Sali and T. L. Blundell: Comparative protein modelling by satisfaction of spatial restraints. Journal of Molecular Biology, 234(3), 779-815 (1993)
44. R. Rodriguez, G. Chinea, N. Lopez, T. Pons and G. Vriend: Homology modeling, model and software evaluation: Three related resources. Bioinformatics, 14(6), 523-528 (1998)
45. R. Maiti, G. H. Van Domselaar, H. Zhang and D. S. Wishart: SuperPose: A simple server for sophisticated structural superposition. Nucleic Acids Research, 32(WEB SERVER ISS.), W590-W594 (2004)
46. M. Wiederstein and M. J. Sippl: ProSA-web: interactive web service for the recognition of errors in threedimensional structures of proteins. Nucleic Acids Research, 35(Web Server issue), W407-410 (2007)
47. D. Eisenberg, R. Lüthy and J. U. Bowie: VERIFY3D: Assessment of protein models with three-dimensional profiles. In, (1997)
48. R. Thomsen and M. H. Christensen: MolDock: A new technique for high-accuracy molecular docking. Journal of Medicinal Chemistry, 49(11), 3315-3321 (2006)
49. R. Wang, X. Fang, Y. Lu and S. Wang: The PDBbind database: Collection of binding affinities for protein-ligand complexes with known three-dimensional structures. Journal of Medicinal Chemistry, 47(12), 2977-2980 (2004)
50. E. Krieger, T. Darden, S. B. Nabuurs, A. Finkelstein and G. Vriend: Making optimal use of empirical energy functions: Force-field parameterization in crystal space. Proteins: Structure, Function and Genetics, 57(4), 678-683 (2004)
51. U. Essmann, L. Perera, M. L. Berkowitz, T. Darden, H. Lee and L. G. Pedersen: A smooth particle mesh Ewald method. The Journal of Chemical Physics, 103(19), 8577-8593 (1995)
52. E. Krieger, J. E. Nielsen, C. A. E. M. Spronk and G. Vriend: Fast empirical pKa prediction by Ewald summation. Journal of Molecular Graphics and Modelling, 25(4), 481-486 (2006)
53. M. G. Lerner, A. L. Bowman and H. A. Carlson: Incorporating dynamics in E. coli dihydrofolate reductase enhances structure-based drug discovery. Journal of Chemical Information and Modeling, 47(6), 2358-2365 (2007)
54. C. A. Lipinski: Lead-and drug-like compounds: The rule-of-five revolution. Drug Discovery Today: Technologies, 1(4), 337-341 (2004)
55. D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward and K. D. Kopple: Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615-2623 (2002)
56. J. A. Lessa, I. C. Mendes, P. R. O. da Silva, M. A. Soares, R. G. dos Santos, N. L. Speziali, N. C. Romeiro, E. J. Barreiro and H. Beraldo: 2-Acetylpyridine thiosemicarbazones: Cytotoxic activity in nanomolar doses against malignant gliomas. European Journal of Medicinal Chemistry, 45(12), 5671-5677 (2010) doi:DOI: 10.1016/j.ejmech.2010.09.021
57. A. Rayan: New tips for structure prediction by comparative modeling. Bioinformation, 3(6), 263-267 (2009)
58. R. A. Laskowski, M. W. MacArthur, D. S. Moss and J. M. Thornton: PROCHECK: a program to check the stereochemical quality of protein structures. Journal of Applied Crystallography, 26(2), 283-291 (1993)
59. P. Benkert, S. C. E. Tosatto and D. Schomburg: QMEAN: A comprehensive scoring function for model quality assessment. Proteins: Structure, Function and Genetics, 71(1), 261-277 (2008)
60. F. Melo and E. Feytmans: Assessing protein structures with a non-local atomic interaction energy. Journal of Molecular Biology, 277(5), 1141-1152 (1998)
61. P. Benkert, M. Biasini and T. Schwede: Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics, 27(3), 343-350 (2011)
62. A. Achari, D. O. Somers, J. N. Champness, P. K. Bryant, J. Rosemond and D. K. Stammers: Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase. Nature Structural Biology, 4(6), 490-497 (1997)
63. M. R. Sawaya and J. Kraut: Loop and subdomain movements in the mechanism of Escherichia coli dihydrofolate reductase: Crystallographic evidence. Biochemistry, 36(3), 586-603 (1997)
64. V. Cody and C. H. Schwalbe: Structural characteristics of antifolate dihydrofolate reductase enzyme interactions. Crystallography Reviews, 12(4), 301-333 (2006)